BiotechTube

dupilumab

ApprovedCompleted
1 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Moderate-to-Severe Atopic Dermatitis

Conditions

Moderate-to-Severe Atopic Dermatitis, Atopic Eczema

Trial Timeline

Jan 11, 2023 → Nov 14, 2024

NCT ID
NCT05590585

About dupilumab

dupilumab is a approved stage product being developed by Sanofi for Moderate-to-Severe Atopic Dermatitis. The current trial status is completed. This product is registered under clinical trial identifier NCT05590585. Target conditions include Moderate-to-Severe Atopic Dermatitis, Atopic Eczema.

What happened to similar drugs?

1 of 8 similar drugs in Moderate-to-Severe Atopic Dermatitis were approved

Approved (1) Terminated (0) Active (7)
✅Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
🔄SHR-1314 + PlaceboJiangsu Hengrui MedicinePhase 3
🔄Indacaterol + ControlNovartisPhase 3
🔄Dupilumab + PlaceboSanofiPhase 3
🔄PonesimodVanda PharmaceuticalsPhase 3
🔄sufentanil sublingual tablet 30 mcgTalpheraPhase 3
🔄Zalviso™ 15 mcgTalpheraPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (20)

NCT IDPhaseStatus
NCT05906706Pre-clinicalCompleted
NCT07316114Pre-clinicalRecruiting
NCT07467564Pre-clinicalRecruiting
NCT07187089ApprovedWithdrawn
NCT07112378Phase 3Recruiting
NCT07052396Pre-clinicalRecruiting
NCT07276425Pre-clinicalRecruiting
NCT06695897Pre-clinicalRecruiting
NCT06693531Pre-clinicalRecruiting
NCT06415175Pre-clinicalActive
NCT06556264ApprovedRecruiting
NCT06352073ApprovedRecruiting
NCT06293053Phase 3Recruiting
NCT05983068ApprovedActive
NCT06234761Pre-clinicalRecruiting
NCT05991323Pre-clinicalActive
NCT06192563Pre-clinicalRecruiting
NCT06169527Pre-clinicalActive
NCT06393946Pre-clinicalActive
NCT05831176Phase 2Active

Competing Products

13 competing products in Moderate-to-Severe Atopic Dermatitis

See all competitors
ProductCompanyStageHype Score
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
44
Tildrakizumab + Placebo + Tildrakizumab + Tildrakizumab + Tildrakizumab + Etanercept + PlaceboSun PharmaceuticalPhase 2/3
42
SHR-1314Jiangsu Hengrui MedicinePhase 1
25
SHR-1314 + PlaceboJiangsu Hengrui MedicinePhase 1/2
32
SHR-1314 + PlaceboJiangsu Hengrui MedicinePhase 3
36
Indacaterol + ControlNovartisPhase 3
40
DeucravacitinibBristol Myers SquibbPre-clinical
33
Dupilumab + PlaceboSanofiPhase 3
40
dupilumabSanofiPre-clinical
26
PonesimodVanda PharmaceuticalsPhase 3
37
sufentanil sublingual tablet 30 mcgTalpheraPhase 3
30
Zalviso™ 15 mcgTalpheraPhase 3
30
sufentanil sublingual 30 mcg tabletTalpheraPhase 3
30